Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
This week, we will discuss a pediatric nephrology trial: is tacrolimus superior to MMF in FRNS and SDNS?
This week, we will discuss a NEJM trial on uncontrolled hypertension: lorundrostat, an aldosterone synthase inhibitor, aims at the hormonal dark side driving resistance.
This week, we will discuss a double header: two single centre ddAVP trials in kidney biopsy from India.
This week, we will discuss the prognostic role of microvascular inflammation in kidney transplantation. Can the capillaries whisper their damage in lesions before antibodies speak? Maybe this study compels us to treat the injury we see, not just the disease we can name…
Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
#TenTweetNephJC returns in 2023! Catch-up rapidly with the biggest trials in nephrology.
— Nephrology Journal Club (@NephJC) January 20, 2023
Up first is NefIgArd.
We all say we hate steroids, but really we love their efficacy but hate their side-effects, right?
IgA nephropathy is again the subject of a steroid trial🧵 pic.twitter.com/sh0xtKPhsP